A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer

PURPOSE: Despite the efficacy of abiraterone, a CYP17A1 inhibitor, in metastatic castration-resistant prostate cancer (CRPC), nearly all patients develop resistance. The purpose of this phase II study was to evaluate mechanisms of resistance to more complete androgen synthesis inhibition with abirat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: McKay, Rana R., Werner, Lillian, Mostaghel, Elahe A., Lis, Rosina, Voznesensky, Olga, Zhang, Zhenwei, Marck, Brett T., Matsumoto, Alvin M., Domachevsky, Liran, Zukotynski, Katherine A., Bhasin, Manoj, Bubley, Glenn J., Montgomery, Bruce, Kantoff, Philip W., Balk, Steven P., Taplin, Mary-Ellen
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315609/
https://ncbi.nlm.nih.gov/pubmed/27683182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0987
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados